ACTIVITY IN THE THIRD QUARTER OF 2017
(Unaudited data)
CUMULATIVE ACTIVITY AS OF THE END OF SEPTEMBER 2017
in thousands of euros
2016
2017
Variation
at current exchange rates
Variation
at constant exchange rates
France
269,803
277,885
+3.0%
+3.0%
Europe (excluding France)
116,530
110,158
-5.5%
-8.0%
North America
46,197
48,699
+5.4%
+5.0%
Other countries
11,187
11,849
+5.9%
+2.5%
Group total
443,717
448,591
+1.1%
+0.3%
in thousands of euros
2016
2017
Variation
at current exchange rates
Variation
at constant exchange rates
Non-proprietary Homeopathic Medicines
230,061
229,933
-0.1%
-0.1%
OTC Specialties
212,781
217,701
+2.3%
+0.7%
Other
875
957
+9.4%
+9.3%
Group total
443,717
448,591
+1.1%
+0.3%
DEVELOPMENT OF BUSINESS IN THE THIRD QUARTER (VARIATION AT CURRENT RATE)
in thousands of euros
1st quarter
2nd quarter
3rd quarter
2016
2017
Var. 17/16
2016
2017
Var. 17/16
2016
2017
Var. 17/16
France
90,494
97,134
+7.3%
80,469
79,328
-1.4%
98,840
101,423
+2.6%
Europe (excluding France)
43,685
40,418
-7.5%
31,572
27,421
-13.1%
41,273
42,319
+2.5%
North America
16,064
18,179
+13.2%
14,113
14,465
+2.5%
16,020
16,055
+0.2%
Other countries
3,846
4,532
+17.8%
4,061
3,191
-21.4%
3,280
4,126
+25.8%
Group total
154,089
160,263
+4.0%
130,215
124,405
-4.5%
159,413
163,923
+2.8%
in thousands of euros
1st quarter
2nd quarter
3rd quarter
2016
2017
Var. 17/16
2016
2017
Var. 17/16
2016
2017
Var. 17/16
Non-proprietary Homeopathic Medicines
80,147
81,016
+1.1%
76,001
74,567
-1.9%
73,913
74,350
+0.6%
OTC Specialties
73,743
78,968
+7.1%
53,719
49,391
-8.1%
85,319
89,342
+4.7%
Other
199
279
+40.2%
495
447
-9.7%
181
231
+27.6%
Group total
154,089
160,263
+4.0%
130,215
124,405
-4.5%
159,413
163,923
+2.8%
HIGHLIGHTS OF THE THIRD QUARTER
Sales revenue in the third quarter of 2017 is growing by 2.8% in comparison to 2016 (the impact of exchange rates is not significant over the period).
Sales increase in particular in Russia, France and the Czech Republic. On the other hand, they decrease in Romania.
OUTLOOK
The level of activity and profitability of the fiscal year will depend on the seasonal pathology of the fourth quarter.
Our company carries on the development of homeopathy in the world with the same determination.
Our next update:
January 25, 2018: at market close, publication of the sales revenue for the year 2017.
Person responsible for financial information: Christian Boiron
Contact for financial information: Véronique Bouscayrol
Investor relations: +33 (0) 4.78.45.63.43 - e-mail : boironfinances@boiron.fr
ISIN Code: FR0000061129 (BOI) - Bloomberg: BOI FP - Reuters: BOIR.PA
The group's financial information and the glossary are online at: www.boironfinance.com
Regulated information
Quaterly financial disclosure:
- Third Quarter Information
Full and original press release in PDF:
https://www.actusnews.com/documents_communiques/ACTUS-0-50678-boi-191017-ca-t3-17-gb.pdf
Receive by email the next press releases of the company by registering on
www.actusnews.com, it′s free
Laboratoires BOIRON was founded in France almost a century ago, under the impetus of homeopathic doctors who wanted to benefit from the most reliable medicines possible. Homeopathic medicines have many advantages in that they can be prescribed and advised in first line whenever relevant, in both urban and hospital settings. All actions aim to contribute to major public health issues.
Homeopathic medicines are obtained from substances called homeopathic strains, according to a manufacturing process described in the pharmacopoeia. These strains can be of plant, animal, mineral or chemical origin.
There are two main families of homeopathic medicines: common name homeopathic medicines and brand name homeopathic medicines (specialties).
BOIRON group centralizes its production and logistics in France. It also has 26 wholly-owned or leased distribution facilities in France and various offices in the countries where it has subsidiaries.
Net sales are distributed geographically as follows: France (52.4%), Europe (22.5%), North America (22.6%) and other (2.5%).
BOIRON 
